Company Description
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies.
It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications.
The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol.
It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis.
In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials.
Incannex Hea
| Country | Australia |
| Founded | 2001 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Joel Bradley Latham |
Contact Details
Address: 401 Docklands Drive, Suite 15, Level 12 Docklands, Victoria, C3 3008 Australia | |
| Phone | 61 409 840 786 |
| Website | incannex.com.au |
Stock Details
| Ticker Symbol | IXHL |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| IPO Price | $9.38 |
| CIK Code | 0001873875 |
| CUSIP Number | 45333L106 |
| ISIN Number | US45333F1093 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joel Bradley Latham | MD, Chief Executive Officer and Executive Director |
| Lekhram Changoer M.Sc. | Chief Technical Officer |
| Joseph Swan | Chief Financial Officer, Treasurer and Secretary |
| Dr. Mark Bleackley | Chief Scientific Officer, Head of Programs and Member of the Advisory Board |
| John Michailidis B.Sc., EMBA, M.A.I.C.D. | Chief Executive Officer of IncannexTM |
| Rosemarie Walsh | Vice President of Clinical Operations and Member of the Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | 8-K | Current Report |
| Mar 5, 2024 | 8-K | Current Report |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 16, 2024 | 8-K | Current Report |
| Feb 14, 2024 | 10-Q | Quarterly Report |
| Feb 1, 2024 | 8-K | Current Report |
| Jan 24, 2024 | 8-K | Current Report |
| Jan 18, 2024 | 8-K | Current Report |
| Jan 17, 2024 | 8-K | Current Report |
| Dec 22, 2023 | 8-K | Current Report |